Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan

Connelly, Luke B. and Le, Ha N. D. (2015) Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan. Sexual Health, 12 6: 520-531. doi:10.1071/SH14241

Author Connelly, Luke B.
Le, Ha N. D.
Title Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan
Journal name Sexual Health   Check publisher's open access policy
ISSN 1449-8987
Publication date 2015-09-28
Year available 2015
Sub-type Article (original research)
DOI 10.1071/SH14241
Open Access Status Not Open Access
Volume 12
Issue 6
Start page 520
End page 531
Total pages 12
Place of publication Collingwood, VIC Australia
Publisher CSIRO
Collection year 2016
Language eng
Formatted abstract
Background: Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.
Keyword Cervical cancer
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Faculty of Health and Behavioural Sciences -- Publications
Official 2016 Collection
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Tue, 08 Dec 2015, 03:49:33 EST by System User on behalf of Faculty of Health and Behavioural Sciences